Sector News

Teva buys more Mylan shares as takeover fight continues

June 22, 2015
Life sciences
Teva has raised its stake in Mylan to 4.61%, which will allow it to take its acquisition bid to court “should it become necessary”.
 
Mylan reincorporated in the Netherlands last year, and under Dutch law owning this amount of shares allows Teva to legally challenge the company’s continued rejections of its $40 billion takeover offer.
 
In a letter last month, Mylan claimed that Teva purchasing these shares violates US antitrust laws, but Teva has countered by saying that such laws should not matter for a company who has moved its domicile abroad.
 
“We note that you have been saying you are a Dutch company when you believe it helps you create unprecedented governance structures, a UK company when it helps you lower your US taxes and a US company when you believe it helps you prevent Teva from purchasing Mylan shares,” CEO Erez Vigodman and chairman Yitzhak Peterburg say.
 
Merger triangle
 
Mylan itself is in the process of attempting to buy Perrigo, but has also been rejected multiple times.
 
The company has accused Teva of using its bid to try and distract from this purchase. In May Mylan implored the Israeli firm to make its intentions clearer before a planned special general meeting where shareholders will vote on whether to endorse the Perrigo offer.
 
Teva has now said that it will limit its shares in Mylan to less than 5% if this meeting is held before September.
 
By George Underwood
 
Source: Pharma Times

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend